CTOs on the Move

Medizone International

www.medizoneint.com

 
Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network. The ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medizoneint.com
  • 350 East Michigan Avenue Suite 500
    Kalamazoo, MI USA 49007
  • Phone: 269.202.5020

Executives

Name Title Contact Details

Similar Companies

Affordable RX

Affordable RX is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canderm Pharma

Canderm Pharma, Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pacific Biomarkers

Pacific Biomarkers is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Osteal Therapeutics

Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.